Clinical trials: Hemostatic Agents
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Multiple Myeloma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in…
- Trial name
- NCT01850524
- Testing
- Ixazomib, Dexamethasone, Lenalidomide
- Where
- 147 sites in United States, Belgium and 5 more
- Volunteers
- 705 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Multiple Myeloma
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
This study has 2 parts: a Dose Escalation Part and a Dose Expansion Part. The goal of the Dose Escalation Part of this clinical research study is to find the highest tolerable dose of nivolumab in combination with ipilimumab and…
- Trial name
- NCT03283046
- Testing
- Nivolumab, Lenalidomide, Dexamethasone
- Sponsor
- M.D. Anderson Cancer Center
Goiter
Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.
Observational study with non-inferiority, prospective, randomized (1: 1) and open-label medical device. The study has 2 treatment groups (HEMOPATCH® versus standard hemostasis).
- Trial name
- NCT05103956
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Relapsed and Refractory Multiple Myeloma (RRMM)
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.
- Trial name
- NCT06479954
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Multiple Myeloma
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
Multiple myeloma (MM) is a rare hematologic malignancy of aberrant plasma cells. There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the therapeutic outcome and prognosis of…
- Trial name
- NCT04499339
- Testing
- SLAMF7 CAR-T
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 38 people
- Sponsor
- Wuerzburg University Hospital
Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies).
- Conditions
- Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT05011045
- Testing
- Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Irreversible Pulpitis, Extremely Deep Caries
Outcome Following Use of Different Concentrations of NaOCl as Wound Lavage and Hemostatic Agent in Partial Pulpotomy
The aim of this randomised control trial is to compare the effect of different concentrations of NaOCl on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
- Conditions
- Irreversible Pulpitis, Extremely Deep Caries, Partial Pulpotomy
- Trial name
- NCT06433245
- Testing
- effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
- Where
- India
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Multiple Myeloma
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide
- Trial name
- NCT02192775
- Testing
- MV-NIS
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arkansas
Hereditary Hemorrhagic Telangiectasia
Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era.
The goal of this interventional study is to determine the incidence of depression, anxiety, sleep disturbances and resilience in a sample of subjects affected by Hereditary Hemorrhagic Telangiectasia.
- Trial name
- NCT05752253
- Testing
- Counseling
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Telangiectasia, Hereditary Hemorrhagic
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs).
- Trial name
- NCT00230672
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Hemophilia A
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion.
- Trial name
- GENEr8-LTE (NCT05768386)
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 172 people
- Sponsor
- BioMarin Pharmaceutical
Multiple Myeloma in Relapse, Multiple Myeloma
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
Pomalidomide either as single therapy or in combination with cyclophosphamide, elotuzumab, bortezomib, or daratumumab are effective treatment regimens in relapsed refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory
- Trial name
- POMAlternative (NCT05555329)
- Testing
- Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Multiple Myeloma
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
This research study is evaluating a combination of four drugs -- lenalidomide, bortezomib, dexamethasone and elotuzumab -- as therapy for newly diagnosed multiple myeloma.
- Trial name
- NCT02375555
- Testing
- Lenalidomide, Elotuzumab, Bortezomib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Hemorrhage, Healthy Volunteers
Healthy Adults Aged 18-55, Three Ukrainian Windlass Tourniquets (SICH, DNIPRO GEN 2, PULS) Compared With CAT Gen 7, and Complete Limb Arterial Occlusion Confirmed by Doppler.
The goal of this clinical trial is to learn if three Ukrainian-made windlass tourniquets (SICH, DNIPRO GEN 2 and PULS) stop arterial blood flow in the arm or leg as well as the Combat Application Tourniquet (CAT Gen 7) does.
- Conditions
- Hemorrhage, Healthy Volunteers, Arterial Occlusion
- Trial name
- TORQUE (NCT07900360)
- Testing
- Windlass-type hemostatic tourniquet SICH, Windlass-type hemostatic tourniquet Dnipro, Windlass-type hemostatic tourniquet PULS, Windlass-type hemostatic tourniquet CAT Gen 7 (reference)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Foundation for Expert Deployment for Governance and Economic Growth (EDGE)
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Research question: Is KRd therapy effective and safe in the real-world Asian patients? Primay objective: To evaluate the effectiveness of KRd in RRMM patients Secondary objectives: To evaluate the effectiveness of investigational…
- Trial name
- NCT05495620
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Volunteers
- 300 people
- Sponsor
- Dong-A University Hospital
Leukemia, Lymphoma
RAT-HEMATO : Return to Work After Malignant Hemopathy
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- RAT-HEMATO (NCT06262789)
- Testing
- "Return-to-work after cancer" consultation
- Where
- 10 sites in France
- Volunteers
- 264 people
- Sponsor
- University Hospital, Angers
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM)…
- Trial name
- CAREMM-012 (NCT07585760)
- Testing
- CM336 Plus Isatuximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.